靶向治疗在白癜风中的研究进展  

Research progress of targeted therapy in vitiligo

作　　者：陈满辉 胡雯[2] 康晓静[2] CHEN Manhui;HU Wen;KANG Xiaojing(Graduate School of Xinjiang Medical University,Urumqi 830054,China;Department of Dermatology and Venereology,People's Hospital of Xinjiang Uygur Autonomous Region,Xinjiang Clinical Research Center for Dermatology and Venereology,Xinjiang Key Laboratory of Dermatology Research,Urumqi 830001,China)

机构地区：[1]新疆医科大学研究生学院,乌鲁木齐830054 [2]新疆维吾尔自治区人民医院皮肤性病科,新疆皮肤病临床医学研究中心,新疆皮肤病研究重点实验室,乌鲁木齐830001

出　　处：《中国免疫学杂志》2024年第12期2676-2679,共4页Chinese Journal of Immunology

基　　金：国家自然科学基金面上项目(82173406)。

摘　　要：白癜风是一种常见的获得性色素脱失性疾病,其特征为皮肤、头发和黏膜中的黑素细胞缺失。白癜风治疗所面临的巨大挑战是难以复色及易于复发。目前白癜风已被明确归类为一种自身免疫性疾病,发病机制极其复杂,涉及遗传和环境因素、氧化应激和自身免疫反应等协同作用导致黑素细胞缺失。随着对白癜风发病机制的深入了解,针对白癜风关键小分子、细胞亚群、免疫相关信号通路的靶向治疗开展了大量的临床试验,靶向治疗将在未来白癜风的治疗中成为主流,本文综述了针对组织常驻记忆T细胞(TRM)通路、JAK-STAT通路、WNT/β-catenin通路等靶向治疗在白癜风中的研究进展。Vitiligo is a common acquired depigmentation disorder characterized by the loss of melanocytes in the skin,hair,and mucous membranes.Its characteristics of difficulty in re-pigmentation and easy recurrence are great challenges for vitiligo treatment.At present,vitiligo has been clearly classified as an autoimmune disease with a complex pathogenesis involving genetic and environmental factors,oxidative stress and autoimmune responses that synergistically promote the loss of melanocytes.With the in-depth understanding of the pathogenesis of vitiligo,a large number of clinical trials have been carried out for targeted therapy of key small molecules,cell subsets,and immune-related signaling pathways in vitiligo.Targeted therapy will become the mainstream in the treatment of vitiligo in the future.Research progress of targeted therapy for tissue resident memory T cells(TRM)pathway,JAK-STAT pathway,and WNT/β-catenin pathway in vitiligo.

关 键 词：白癜风 靶向治疗 TRM JAK抑制剂 WNT通路 

分 类 号：R751.05[医药卫生—皮肤病学与性病学]